ALLMedicine™ Acute Bronchospasm Center

Feb 9th, 2020 - Reference Range Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet. [1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke...

Feb 9th, 2020 - Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet.[1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke.[3] In the blood...

Nov 27th, 2019 - In asthma, acute bronchospasm is driven by contractile forces of airway smooth muscle (ASM). These forces can be imaged in the cultured ASM cell or assessed in the muscle strip and the tracheal/bronchial ring, but in each case, the ASM is studied ...

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

Sep 9th, 2019 - Adenosine is frequently used during coronary angiography to induce hyperaemia and allow operators to perform quantitative measurements of lesion severity. Acute bronchospasm is a recognised side effect relating to the activation of 'off target' A2...

NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

Sep 8th, 2020 - TRELEGY ELLIPTA is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta2-adrenergic agonist (LABA), indicated for: •the maintenance treatment of patients with c...

Aug 2nd, 2020 - DULERA is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for: Treatment of asthma in patients 5 years of age and older. (1.1) Important Limitation of Use: Not indicated for the relief ...

Aug 2nd, 2020 - ASMANEX HFA is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. (1.1) Important limitations: Not indicated for the relief of acute bronchospasm. (1.1) ASMANEX® HFA is ind...

Jul 22nd, 2020 - BREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BREZTRI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthm...

Jul 12th, 2020 - FLOVENT HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Important Limitation of Use Flovent HFA is not indicated for the relief of acute bronchospasm. FLOVENT HFA is an inhaled c...

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

Aug 1st, 2014 - The FDA approved another once-daily bronchodilator, olodaterol (Striverdi Respimat), for maintenance treatment of chronic obstructive pulmonary disease (COPD). Approved indications for the long-acting beta-adrenergic agonist (LABA) drug included l...

NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.